Abstract:

The development of tyrosine kinase inhibitors（TKIs） has revolutionized the therapy of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia（Ph+ALL）. The prospects for a favorable therapeutic outcome in patients with Ph+ALL have improved markedly， as demonstrated in a recent study that has combined intensive chemotherapy with TKIs. HSCT is no longer universally recommended for Ph+ALL. These would give rise to our thinking of the therapy.

Key words: tyrosine kinase inhibitors, Philadelphia chromosome-positive, acute lymphoblastic leukemia

摘要：

靶向药物酪氨酸激酶抑制剂（TKIs）的发展，极大地改变了人们对儿童Ph染色体阳性急性淋巴细胞白血病（Ph+ALL）的认识。在强化疗联合TKIs治疗取得优越疗效的基础上，造血干细胞移植（HSCT）的地位也出现了争议，进而引发了对HSCT治疗方案的思考。

关键词: 酪氨酸激酶抑制剂, Ph染色体阳性, 急性淋巴细胞白血病